NO177716C - Fremgangsmåte for fremstilling av terapeutisk aktive polypeptider, DNA-sekvens, ekspresjonsvektor og antistoff - Google Patents

Fremgangsmåte for fremstilling av terapeutisk aktive polypeptider, DNA-sekvens, ekspresjonsvektor og antistoff

Info

Publication number
NO177716C
NO177716C NO902444A NO902444A NO177716C NO 177716 C NO177716 C NO 177716C NO 902444 A NO902444 A NO 902444A NO 902444 A NO902444 A NO 902444A NO 177716 C NO177716 C NO 177716C
Authority
NO
Norway
Prior art keywords
pro
cys
lys
gly
antibody
Prior art date
Application number
NO902444A
Other languages
English (en)
Other versions
NO177716B (no
NO902444D0 (no
NO902444L (no
Inventor
Enno Christophers
Oliver Wiedow
Jens-Michael Schroder
Michael Derek Edge
David Pioli
Original Assignee
Zeneca Ltd
Ici Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB898913349A external-priority patent/GB8913349D0/en
Priority claimed from GB898913346A external-priority patent/GB8913346D0/en
Priority claimed from GB898921613A external-priority patent/GB8921613D0/en
Priority claimed from GB898924717A external-priority patent/GB8924717D0/en
Application filed by Zeneca Ltd, Ici Plc filed Critical Zeneca Ltd
Publication of NO902444D0 publication Critical patent/NO902444D0/no
Publication of NO902444L publication Critical patent/NO902444L/no
Publication of NO177716B publication Critical patent/NO177716B/no
Publication of NO177716C publication Critical patent/NO177716C/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C07K14/39—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO902444A 1989-06-09 1990-06-01 Fremgangsmåte for fremstilling av terapeutisk aktive polypeptider, DNA-sekvens, ekspresjonsvektor og antistoff NO177716C (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB898913349A GB8913349D0 (en) 1989-06-09 1989-06-09 Polypeptides
GB898913346A GB8913346D0 (en) 1989-06-09 1989-06-09 Polypeptide analogues
GB898921613A GB8921613D0 (en) 1989-09-25 1989-09-25 Polypeptides-1st update
GB898924717A GB8924717D0 (en) 1989-11-02 1989-11-02 Polypeptides

Publications (4)

Publication Number Publication Date
NO902444D0 NO902444D0 (no) 1990-06-01
NO902444L NO902444L (no) 1990-12-10
NO177716B NO177716B (no) 1995-07-31
NO177716C true NO177716C (no) 1995-11-08

Family

ID=27450350

Family Applications (1)

Application Number Title Priority Date Filing Date
NO902444A NO177716C (no) 1989-06-09 1990-06-01 Fremgangsmåte for fremstilling av terapeutisk aktive polypeptider, DNA-sekvens, ekspresjonsvektor og antistoff

Country Status (16)

Country Link
US (4) US5464822A (no)
EP (1) EP0402068B1 (no)
JP (1) JP2989853B2 (no)
AT (1) ATE131493T1 (no)
AU (1) AU636148B2 (no)
CA (1) CA2018592C (no)
DE (1) DE69024104T2 (no)
DK (1) DK0402068T3 (no)
ES (1) ES2080800T3 (no)
FI (1) FI106471B (no)
GR (1) GR3018401T3 (no)
IE (1) IE70520B1 (no)
IL (1) IL94602A (no)
NO (1) NO177716C (no)
NZ (1) NZ233974A (no)
PT (1) PT94326B (no)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO177716C (no) * 1989-06-09 1995-11-08 Zeneca Ltd Fremgangsmåte for fremstilling av terapeutisk aktive polypeptider, DNA-sekvens, ekspresjonsvektor og antistoff
EP0458537B1 (en) * 1990-05-24 1999-03-31 Zeneca Limited Use of a therapeutic compound for the treatment of bronchitis
DE69129083T2 (de) * 1990-05-24 1998-07-09 Zeneca Ltd Therapeutisches Mittel zur Vorbeugung und Behandlung des Atemnotsyndroms bei Erwachsenen
US5162348A (en) * 1990-05-24 1992-11-10 Imperial Chemical Industries Plc Treatment of cystic fibrosis
US5734014A (en) * 1992-08-11 1998-03-31 Tsumura & Co. Elafin derivative
US8606851B2 (en) 1995-06-06 2013-12-10 Wayport, Inc. Method and apparatus for geographic-based communications service
US5835061A (en) * 1995-06-06 1998-11-10 Wayport, Inc. Method and apparatus for geographic-based communications service
EP0834556A1 (en) * 1996-09-25 1998-04-08 Academisch Ziekenhuis Leiden Methods for culturing cells
US7034132B2 (en) 2001-06-04 2006-04-25 Anderson David W Therapeutic polypeptides, nucleic acids encoding same, and methods of use
AU2001241913A1 (en) * 2000-03-01 2001-09-12 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for wound treatment
US7247704B2 (en) 2000-12-18 2007-07-24 Arriva Pharmaceuticals, Inc. Multifunctional protease inhibitors and their use in treatment of disease
US7041787B2 (en) * 2000-12-29 2006-05-09 Kimberly-Clark Worldwide, Inc. Design and use of advanced zinc chelating peptides to regulate matrix metalloproteinases
US6600057B2 (en) 2000-12-29 2003-07-29 Kimberly-Clark Worldwide, Inc. Matrix metalloproteinase inhibitors
US20030119073A1 (en) * 2001-12-21 2003-06-26 Stephen Quirk Sensors and methods of detection for proteinase enzymes
EP1476573B1 (en) 2002-01-28 2010-01-06 Ambion, Inc. Crude biological derivatives competent for nucleic acid detection
CN1838964A (zh) * 2002-04-25 2006-09-27 斯克里普斯研究学院 肺病的治疗与预防
FR2849375B1 (fr) * 2002-12-30 2006-10-20 Jean Noel Thorel Compositions cosmetiques, par exemple pour traiter le vieillissement cutane photo-induit
EP1620121A2 (en) * 2003-05-07 2006-02-01 VIB vzw The use of a polypeptide domain of slpi to modulate the tumorigenic and metastatic potential of cancer cells
WO2006122404A1 (en) * 2005-05-16 2006-11-23 Her Majesty The Queen In Right As Represented By The Minister Of Health Trappin-2 (elafin) inhibits hiv
US7964350B1 (en) 2007-05-18 2011-06-21 Applied Biosystems, Llc Sample preparation for in situ nucleic acid analysis
EP2955233A1 (en) 2008-12-19 2015-12-16 Life Technologies Corporation Proteinase K inhibitors, methods and compositions therefor
GB201003559D0 (en) * 2010-03-03 2010-04-21 Proteo Biotech Ag Novel use of elafin
US20230285523A1 (en) * 2021-12-20 2023-09-14 Tiakis Biotech Ag Use of elafin in the treatment of covid-19

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4746729A (en) * 1986-07-30 1988-05-24 Kuettner Klaus E Cartilage-derived leukocyte elastase-inhibitor
US6024983A (en) * 1986-10-24 2000-02-15 Southern Research Institute Composition for delivering bioactive agents for immune response and its preparation
EP0460072B1 (en) * 1989-02-23 1998-02-04 Center For Blood Research, Inc. Human elastase inhibitor
NO177716C (no) * 1989-06-09 1995-11-08 Zeneca Ltd Fremgangsmåte for fremstilling av terapeutisk aktive polypeptider, DNA-sekvens, ekspresjonsvektor og antistoff

Also Published As

Publication number Publication date
GR3018401T3 (en) 1996-03-31
DK0402068T3 (da) 1996-04-22
FI106471B (fi) 2001-02-15
EP0402068A1 (en) 1990-12-12
FI902880A0 (fi) 1990-06-08
NO177716B (no) 1995-07-31
EP0402068B1 (en) 1995-12-13
CA2018592C (en) 2002-08-27
US5464822A (en) 1995-11-07
PT94326A (pt) 1991-02-08
JPH03148299A (ja) 1991-06-25
NO902444D0 (no) 1990-06-01
US20060068480A1 (en) 2006-03-30
IL94602A0 (en) 1991-04-15
CA2018592A1 (en) 1990-12-09
PT94326B (pt) 1997-01-31
IE70520B1 (en) 1996-12-11
AU636148B2 (en) 1993-04-22
US20020187535A1 (en) 2002-12-12
DE69024104T2 (de) 1996-06-13
NO902444L (no) 1990-12-10
NZ233974A (en) 1993-05-26
DE69024104D1 (de) 1996-01-25
IE902006L (en) 1990-12-09
ES2080800T3 (es) 1996-02-16
JP2989853B2 (ja) 1999-12-13
ATE131493T1 (de) 1995-12-15
IL94602A (en) 1996-06-18
AU5680890A (en) 1990-12-13
US6893843B2 (en) 2005-05-17
US6245739B1 (en) 2001-06-12

Similar Documents

Publication Publication Date Title
NO177716C (no) Fremgangsmåte for fremstilling av terapeutisk aktive polypeptider, DNA-sekvens, ekspresjonsvektor og antistoff
RU95115239A (ru) Аналог эритропоэтина
NO960309L (no) Agonister og antagonister for humaninterleukin-10
CA2184584A1 (en) Vascular endothelial growth factor 2
DE69428214D1 (de) Transformierender wachstumsfaktor alpha h1
RU93005089A (ru) Производное белка с человека, днк, клетка, фармацевтическая композиция, применение производного белка с, способ получения
ATE150319T1 (de) Behandlung von asthma
ATE64619T1 (de) Menschliches apolipoprotein a1 sowie dessen variante, exprimiert in escherichia coli.
EP0225020A3 (en) Peptides comprising, in sequence, units selected from the amino-acid residues 17 to 24 of vip
DK0434605T3 (da) Ny fremgangsmåde til fremstilling af ikke-fusioneret protein i E.coli
BR0312889A (pt) Polipeptìdeo t20 peguilado
IL90334A0 (en) Genetic transformation of b.thuringiensis,vectors used therefor,host cells transformed by the vectors and use of said cells as insecticides
DE68917837D1 (de) Peptid-Verbindungen.
DK288789D0 (da) Peptider og syreadditionssalte deraf, deres fremstilling og anvendelse
AU2190288A (en) Vector for the expression of proteins of the HIV-2 virus, one of the casual agents of AIDS, cell culture infected or transformed by this vector, proteins obtained, vaccine and antibodies obtained
ATE240398T1 (de) Von kaposi-sarkom assoziiertem herpes-virus (kshv,hhv-8) kodiertes polypeptid und dessen verwendung in diagnostik und therapie
CA2118498A1 (en) A novel anti-neoplastic cytokine
WO1992014818A3 (en) Entomopoxvirus expression system comprising spheroidin or thymidine-kinase sequences
TH14583EX (th) จีนที่มีรหัสของเมกะคาริโอไซท์โพเทนชิเอเตอร์
AU5110390A (en) Cdna coding for placental protein 9 (pp9), the isolation and use thereof
NO905375D0 (no) Fremg. og preparater for behandling av pattedyr-infeksjoner under anv. av medikamenter som omfatter hymenoptera venom, protein- eller polypepti-komponenter derav, eller analoger av slike protein- eller polypeptid-komponenter.
IT8647992A0 (it) Metodo per il trattamento di malattie autoimmunitarie,basato sull'uso del bendazac e di altri farmaci che inibiscono specificamente i processi di denaturazione proteica responsabili della reazione autoimmunitaria
CA2080355A1 (en) Isolated Viral Protein Cytokine Antagonists

Legal Events

Date Code Title Description
MK1K Patent expired